Neurochemical Journal

, Volume 9, Issue 3, pp 201–205 | Cite as

The analog of arginine-vasopressin (6-9) fragment, Ac-D-SPRG, exhibits antidepressant action in rats in case of intranasal injection

  • A. S. Belyakova
  • A. A. Sinjushin
  • O. G. Voskresenskaya
  • A. A. Kamensky
  • V. P. Golubovich
Experimental Articles


The antidepressant properties of newly synthesized analog of arginine-vasopressin fragment analog, Ac-D-SPRG, were tested using Porsolt’s swimming test on white rats. It was demonstrated that this substance when injected intranasally decreases the depression in comparison with the control group.


depression forced swimming test arginine-vasopressin neuropeptide intranasal injection 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Du Vigneaud, V., Ressler, C., Swan, J.M., Roberts, C.W., and Katsoyannis, P.G., J. Am. Chem. Soc., 1954, vol. 76, pp. 3115–3121.CrossRefGoogle Scholar
  2. 2.
    Du Vigneaud, V., The isolation and proof of structure of the vasopressins and the synthesis of octapeptide amines with pressor-antidiuretic activity, Proceedings of the Third International Congress of Biochemistry, New York: Academic Press, Inc., 1956, pp. 49–54.Google Scholar
  3. 3.
    De Wied, D., Int. J. Neuropharmacol., 1965, vol. 4, pp. 157–167.CrossRefGoogle Scholar
  4. 4.
    De Wied, D., Nature, 1971, vol. 232, pp. 58–60.CrossRefPubMedGoogle Scholar
  5. 5.
    De Wied, D., Life Sci., 1976, vol. 19, pp. 685–690.CrossRefPubMedGoogle Scholar
  6. 6.
    De Wied, D. and Gispen, W.N., Behavioral effects of peptides, in Peptides in Neurobiology, US: Springer, 1977, pp. 397–425.CrossRefGoogle Scholar
  7. 7.
    Tonkovich, I.N., Mathematical modeling and prediction of degradation of peptide compound, PhD Thesis, Minsk, 2000.Google Scholar
  8. 8.
    Burbach, J.P., Kovacs, G.L., de Wied, D., van Nispen, J.W., and Greven, H.M., Science, 1983, vol. 221, pp. 1310–1312.CrossRefPubMedGoogle Scholar
  9. 9.
    Lin, C., Lin, R., and Du, Y., Hippocampus, 1993, vol. 3, pp. 193–204.CrossRefGoogle Scholar
  10. 10.
    Golubovich, V.P., Martinovich, V.P., Usenko, A.P., Slobodchikova, L.K., Titov, S.A., and Ashmarin, I.P., Pharm. Chem. J., 1988, vol. 22, pp. 440–444.CrossRefGoogle Scholar
  11. 11.
    Ponomareva, N.S., Voskresenskaya, O.G., Kamensky, A.A., Golubovich, V.P., and Ashmarin, I.P., Zhurn. Vyssh. Nerv. Deiat. im. I.P. Pavlova, 1998a, vol. 48, pp. 471–477.Google Scholar
  12. 12.
    Ponomareva, N.S., Voskresenskaya, O.G., Kamensky, A.A., Golubovich, V.P., and Ashmarin, I.P., Russ. J. Physiol., 1998b, vol. 84, pp. 1363–1369.Google Scholar
  13. 13.
    Porsolt, R.D., Anton, G., Blavet, N., and Jaltre, M., Europ. J. Pharmacol., 1978, vol. 47, pp. 379–386.CrossRefGoogle Scholar
  14. 14.
    Detke, M.J., Rickels, M., and Lucki, I., Psychopharmacology, 1995, vol. 121, pp. 66–72.CrossRefPubMedGoogle Scholar
  15. 15.
    Pietrowsky, R., Struben, C., Molle, M., Fehm, H.L., and Born, J., Biol. Psychiatry, 1996, vol. 39, pp. 332–340.CrossRefPubMedGoogle Scholar
  16. 16.
    Born, J., Lange, T., Kern, W., McGregor, G.P., Bickel, U., and Fehm, H.L., Nature Neurosci., 2002, vol. 5, pp. 514–516.CrossRefPubMedGoogle Scholar
  17. 17.
    Koolhaas, J.M., Everts, H., de Ruiter, A.J., de Boer, S.F., and Bohus, B., Progr. Brain. Res., 1998, vol. 119, pp. 437–448.CrossRefGoogle Scholar
  18. 18.
    Landgraf, R., Wigger, A., Holsboer, F., and Neumann, I.D., J. Neuroendocrinol., 1999, vol. 11, pp. 405–407.CrossRefPubMedGoogle Scholar
  19. 19.
    Wigger, A., Sanchez, M.M., Mathys, K.C., Ebner, K., Frank, E., Liu, D., et al., Neuropsychopharmacology, 2004, vol. 29, pp. 1–14.CrossRefPubMedGoogle Scholar
  20. 20.
    Tanoue, A., Ito, S., Honda, K., Oshikawa, S., Kitagawa, Y., Koshimizu, T.A., et al., J. Clin. Invest., 2004, vol. 113, pp. 302–309.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Griebel, G., Simiand, F., Gal, C.S.-L., Wagnon, J., Pascal, M., Scatton, B., et al., Proc. Natl. Acad. Sci. USA, 2002, vol. 99, pp. 6370–6375.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Griebel, G., Simiand, J., Stemmelin, J., Serradeil-Le, G.C., and Steinberg, R., The vasopressin V1b receptor as a therapeutic target in stress-related disorders, in Current Drug Targets-CNS and Neurological Disorders, Princeton (NJ): Bentham Science Publishers, 2003, vol. 2, pp. 191–200.CrossRefPubMedGoogle Scholar
  23. 23.
    Serradeil-Le, G.C., Wagnon, J., Simiand, J., Griebel, G., Lacour, C., Guillon, G., et al., J. Pharmacol. Exp. Ther., 2002, vol. 300, pp. 1122–1130.CrossRefGoogle Scholar
  24. 24.
    Stemmelin, J., Lukovic, L., Salome, N., and Griebel, G., Neuropsychopharmacology, 2005, vol. 30, pp. 35–42.CrossRefPubMedGoogle Scholar
  25. 25.
    Voskresenskaya, O., Kamensky, A., and Golubovich, V., Europ. Neuropsychopharmacol., 2007, vol. 17, pp. S249–S250.CrossRefGoogle Scholar
  26. 26.
    Iijima, M., Yoshimizu, T., Shimazaki, T., Tokugawa, K., Fukumoto, K., Kurosu, S., Kuwada, T., Sekiguchi, T., and Chaki, S., Brit. J. Pharmacol., 2014, vol. 171, pp. 3511–3525.CrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2015

Authors and Affiliations

  • A. S. Belyakova
    • 1
  • A. A. Sinjushin
    • 2
  • O. G. Voskresenskaya
    • 1
  • A. A. Kamensky
    • 1
  • V. P. Golubovich
    • 3
  1. 1.Department of Human and Animal PhysiologyM. V. Lomonosov Moscow State UniversityMoscowRussia
  2. 2.Department of GeneticsM.V. Lomonosov Moscow State UniversityMoscowRussian Federation
  3. 3.Institute of Bioorganic ChemistryNational Academy of SciencesMinskRepublic of Belarus

Personalised recommendations